Archangels — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Cytomoscytomos.comin𝕏Seed · Jun 2022 · $2M
Cytomos develops AuraCyt®, a microelectronics-based biotechnology platform for real-time single-cell analytics in bioprocessing and cell and gene therapy manufacturing.
BiotechDeep TechMedical Devices
Co-investorsBritish Business BankOld College CapitalScottish Enterprise
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Hearing Diagnostics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.